Regulation of the mRNA half-life in breast cancer

Paola Griseri, Gilles Pagès

Research output: Contribution to journalArticlepeer-review


The control of the half-life of mRNA plays a central role in normal development and in disease progression. Several pathological conditions, such as breast cancer, correlate with deregulation of the half-life of mRNA encoding growth factors, oncogenes, cell cycle regulators and inflammatory cytokines that participate in cancer. Substantial stability means that a mRNA will be available for translation for a longer time, resulting in high levels of protein gene products, which may lead to prolonged responses that subsequently result in over-production of cellular mediators that participate in cancer. The stability of these mRNA is regulated at the 3'UTR level by different mechanisms involving mRNA binding proteins, micro-RNA, long non-coding RNA and alternative polyadenylation. All these events are tightly interconnected to each other and lead to steady state levels of target mRNAs. Compelling evidence also suggests that both mRNA binding proteins and regulatory RNAs which participate to mRNA half-life regulation may be useful prognostic markers in breast cancers, pointing to a potential therapeutic approach to treatment of patients with these tumors. In this review, we summarize the main mechanisms involved in the regulation of mRNA decay and discuss the possibility of its implication in breast cancer aggressiveness and the efficacy of targeted therapy.

Original languageEnglish
Pages (from-to)323-334
Number of pages12
JournalWorld Journal of Clinical Oncology
Issue number3
Publication statusPublished - Aug 10 2014


  • Alternative polyadenylation
  • Breast cancer
  • MicroRNA
  • mRNA stability
  • RNA binding proteins

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Regulation of the mRNA half-life in breast cancer'. Together they form a unique fingerprint.

Cite this